Drug
Aln Agt01
Aln Agt01: highest development phase Phase 2, developed by Alnylam Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-AGT01 NCT04936035 | Phase 2 | Hypertension |
| ALN-AGT01 NCT03934307 | Phase 1 | Hypertension |
Latest
No recent events.
Follow Aln Agt01 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.